...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
【24h】

Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.

机译:肝胆闪烁显像仪延迟的肠道显像与囊性纤维化相关肝病患者对长期接受熊去氧胆酸治疗的反应有关。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND/AIMS: Abnormalities of biliary drainage have been documented at hepatobiliary scintigraphy in many but not all patients studied with cystic fibrosis-associated liver disease. Ursodeoxycholic acid was shown to be beneficial in this disease, mainly by improving biliary secretion. Therefore, patients with impaired biliary drainage are expected to obtain the greatest benefit from this treatment. METHODS: We evaluated the effects of long-term treatment with ursodeoxycholic acid in 36 patients with cystic fibrosis-associated liver disease, and compared the response in patients presenting a normal (n=18) or delayed time of intestinal visualization (n=18) at baseline hepatobiliary scintigraphy. RESULTS: The mean treatment duration was 58+/-26 (S.D.) months and 63+/-29 months in the groups with normal or delayed time of intestinal visualization, respectively. The time of intestinal visualization decreased (57+/-23%, p<0.001) from baseline in patients with initially abnormal values and became normal in four (22%). Treatment failure, i.e. lack of sustained normalization of serum liver enzymes or the occurrence of a clinically relevant adverse event, was more frequently observed in patients with a normal time of intestinal visualization at baseline (OR, 5.50; 95% CI, 1.32-22.7). When only clinically relevant adverse events were considered, they occurred in six of the latter patients (liver transplantation in one case, development of ultrasographic or endoscopic signs of portal hypertension in six cases), but in only one patient (development of portal hypertension) in the group with delayed time of intestinal visualization (OR, 10.82; 95% CI, 1.17-100.4). CONCLUSIONS: Delayed intestinal visualization at hepatobiliary scintigraphy in patients with cystic fibrosis-associated liver disease seems to predict a better response to ursodeoxycholic acid.
机译:背景/目的:在许多胆囊性纤维化相关性肝病患者中,并非所有患者,肝胆显像检查均已发现胆汁引流异常。熊去氧胆酸被证明对该病有益,主要是通过改善胆汁分泌。因此,胆道引流受损的患者有望从这种治疗中获得最大的收益。方法:我们评估了长期使用熊去氧胆酸治疗36例与囊性纤维化相关的肝病的效果,并比较了表现正常(n = 18)或肠道可视化时间延迟(n = 18)的患者的反应在基线时进行肝胆闪烁显像。结果:肠道显像时间正常或延迟的组的平均治疗时间分别为58 +/- 26(S.D.)个月和63 +/- 29个月。具有初始异常值的患者的肠显像时间比基线时间减少(57 +/- 23%,p <0.001),而四分之一(22%)则恢复正常。在基线时具有正常肠显像时间的患者中更经常观察到治疗失败,即血清肝酶缺乏持续的正常化或临床相关不良事件的发生(OR,5.50; 95%CI,1.32-22.7) 。如果仅考虑与临床相关的不良事件,则后者发生在六名患者中(一例发生肝移植,六例发生超声检查或内窥镜检查显示门脉高压),而另一例仅发生一名患者(发生门脉高压)。肠道可视化时间延迟的组(OR,10.82; 95%CI,1.17-100.4)。结论:与胆囊性纤维化相关的肝病患者在肝胆闪烁显像时延迟肠显像似乎预示着对熊去氧胆酸的更好反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号